2021 Consensus Conference to Implement Optimal VTE Prophylaxis in Trauma

项目总监/首席调查员(最后、第一、中间)：Costantini、Todd W&Haut、Elliott R 拟议的2021年创伤预防VTE最佳共识会议将召开 在互动论坛中(面对面和在线)由知名和初级科学家和实践者组成的多学科小组 在此期间，静脉血栓栓塞症(VTE)预防科学的现状和未来 呈上了。VTE包括深静脉血栓形成(DVT)和肺栓塞(PE)，是导致 重大创伤后患者的发病率和死亡率。通过降低VTE发生率改善患者预后 创伤患者将需要实施循证建议，优化现有的护理途径， 以及未来药物预防的新治疗策略的开发。 会议的主要目标是促进与及时提供药理学静脉血栓栓塞术相关的研究 预防，支持开发教育平台和临床护理路径，以改进实施 目前的指南，并为创伤中的VTE预防制定未来的研究目标。会议的目标是： 1)确定创伤临床医生、外科医生接受的高危创伤患者的静脉血栓栓塞术预防指南 专科医生、护士、药剂师和所有为受伤病人提供护理的专科医生； 2)将本指南分发给各专业组织； 3)应对在医疗保健系统中传播和实施这些准则的挑战； 4)确定研究优先事项，以衡量有VTE风险的受伤患者的短期和长期结果，研究 执行协商一致的指南，并研究预防静脉血栓栓塞症的新的药理学方法； 5)将受伤患者和民众的声音与VTE结合起来，促进真正以患者为中心的护理研究； 6)提供机会，让初级调查人员、妇女和对创伤感兴趣的代表不足的少数族裔参与进来 和VTE，以确保不同调查小组的渠道，并刺激新的赠款申请。 为鼓励初级调查员及见习生出席，本署将颁发五项初级调查员旅费奖，以涵盖 旅费和登记费。这些奖项的颁发将通过国家保护联盟宣布 创伤研究的成员组织(超过14,000名成员)和相关的专业组织 由代表不足的科学家和实践者组成。获奖者将被鼓励作为作者参与 筹备会议记录以供出版。包括圆桌讨论和网络活动。 在会议议程中促进初级和高级与会者之间的互动。 这次会议将与NHLBI的总体战略愿景保持一致：“开发和优化新的诊断和 预防、治疗和治愈HLBS疾病的治疗策略“(Obj.5)、“优化临床和实施” 改善健康和减少疾病的研究“(Obj.6)，并“进一步发展、多样化和维持科学的 能够完成NHLBI任务的劳动力“(Obj.7)。 OMB编号0925-0001/0002(2020年03版，2023年2月28日)第1页续格式页

Program Director/Principal Investigator (Last, First, Middle): Costantini, Todd W & Haut, Elliott R The proposed 2021 Consensus Conference to Implement Optimal VTE Prophylaxis in Trauma will convene a multidisciplinary group of established and junior scientists and practitioners in an interactive forum (in-person and online) during which the current state and future of the science on venous thromboembolism (VTE) prophylaxis will be presented. VTE, which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a significant cause of morbidity and mortality for patients following major trauma. Improving patient outcomes by decreasing VTE rates in trauma patients will require implementation of evidence-based recommendations, optimization of current care pathways, and development of novel therapeutic strategies for pharmacologic prophylaxis in the future. The conference primary objectives are to promote research related to delivering timely pharmacologic VTE prophylaxis, to support the development of education platforms and clinical care pathways to improve implementation of current guidelines, and to develop future research objectives for VTE prophylaxis in trauma. The conference aims are to: 1) Define guidelines for VTE prophylaxis in high-risk trauma patients that are accepted by trauma clinicians, surgical subspecialists, nurses, pharmacists, and all specialists who provide care to injured patients; 2) Disseminate these guidelines to respective specialty organizations; 3) Address challenges to the dissemination and implementation of these guidelines across healthcare systems; 4) Define research priorities to measure short- and long-term outcomes for injured patients at risk for VTE, study the implementation of consensus guidelines, and investigate novel pharmacologic approaches to VTE prophylaxis; 5) Integrate the voice of injured patients and people with VTE to promote truly patient-centered care research; 6) Provide an opportunity to engage junior investigators, women, and underrepresented minorities interested in trauma and VTE to ensure the pipeline of a diverse group of investigators and spur new grant applications. To encourage attendance by junior investigators and trainees, 5 junior investigator travel awards will be made to cover travel and registration expenses. The offering of these awards will be announced through the Coalition for National Trauma Research’s member organizations (to their more than 14,000 members) and related professional organizations comprising underrepresented scientists and practitioners. Awardees will be encouraged to participate as authors in the preparation of the conference proceedings for publication. Roundtable discussions and networking activities are included in the conference agenda to facilitate interaction between junior and senior participants. The conference will align with NHLBI’s overarching strategic vision to: “Develop and optimize novel diagnostic and therapeutic strategies to prevent, treat, and cure HLBS diseases” (Obj. 5), to “Optimize clinical and implementation research to improve health and reduce disease” (Obj. 6), and to “Further develop, diversify, and sustain a scientific workforce capable of accomplishing the NHLBI’s mission” (Obj. 7). OMB No. 0925-0001/0002 (Rev. 03/2020 Appr to 02/28/2023) Page 1 Continuation Format Page